Literature DB >> 33230870

Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights.

Btissame El Hassouni1, Alessandro Gregori1, Jisce R Puik2, Dongmei Deng3, Geert Kazemier4, Elisa Giovannetti1,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33230870      PMCID： PMC8649010          DOI： 10.1002/onco.13606

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  5 in total

1.  Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.

Authors:  Leore T Geller; Michal Barzily-Rokni; Tal Danino; Oliver H Jonas; Noam Shental; Deborah Nejman; Nancy Gavert; Yaara Zwang; Zachary A Cooper; Kevin Shee; Christoph A Thaiss; Alexandre Reuben; Jonathan Livny; Roi Avraham; Dennie T Frederick; Matteo Ligorio; Kelly Chatman; Stephen E Johnston; Carrie M Mosher; Alexander Brandis; Garold Fuks; Candice Gurbatri; Vancheswaran Gopalakrishnan; Michael Kim; Mark W Hurd; Matthew Katz; Jason Fleming; Anirban Maitra; David A Smith; Matt Skalak; Jeffrey Bu; Monia Michaud; Sunia A Trauger; Iris Barshack; Talia Golan; Judith Sandbank; Keith T Flaherty; Anna Mandinova; Wendy S Garrett; Sarah P Thayer; Cristina R Ferrone; Curtis Huttenhower; Sangeeta N Bhatia; Dirk Gevers; Jennifer A Wargo; Todd R Golub; Ravid Straussman
Journal:  Science       Date:  2017-09-15       Impact factor: 47.728

2.  Tumor microbiome: Pancreatic cancer and duodenal fluids contain multitudes, …but do they contradict themselves?

Authors:  Laura L Meijer; Eline S Zwart; Bernd W Brandt; Reina Mebius; Dongmei Deng; Elisa Giovannetti; Egija Zaura; Geert Kazemier
Journal:  Crit Rev Oncol Hematol       Date:  2019-11-02       Impact factor: 6.312

3.  Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.

Authors:  Erick Riquelme; Yu Zhang; Liangliang Zhang; Maria Montiel; Michelle Zoltan; Wenli Dong; Pompeyo Quesada; Ismet Sahin; Vidhi Chandra; Anthony San Lucas; Paul Scheet; Hanwen Xu; Samir M Hanash; Lei Feng; Jared K Burks; Kim-Anh Do; Christine B Peterson; Deborah Nejman; Ching-Wei D Tzeng; Michael P Kim; Cynthia L Sears; Nadim Ajami; Joseph Petrosino; Laura D Wood; Anirban Maitra; Ravid Straussman; Matthew Katz; James Robert White; Robert Jenq; Jennifer Wargo; Florencia McAllister
Journal:  Cell       Date:  2019-08-08       Impact factor: 41.582

4.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

5.  Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer.

Authors:  Robert W Corty; Benjamin W Langworthy; Jason P Fine; John B Buse; Hanna K Sanoff; Jennifer L Lund
Journal:  Oncologist       Date:  2020-03-17
  5 in total
  1 in total

1.  In Reply.

Authors:  Robert W Corty
Journal:  Oncologist       Date:  2021-11-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.